Abstract
Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. To evaluate demographic, social and clinical factors that could be used to predict effectiveness and stratify response to biologic therapies in psoriasis. Using a multicentre, observational, prospective pharmacovigilance study (BADBIR), we identified biologic-naive patients starting biologics with outcome data at 6 (n = 3079) and 12 (n = 3110) months. Associations between 31 putative predictors and outcomes were investigated in univariate and multivariable regression analyses. Potential stratifiers of treatment response were investigated with statistical interactions. Eight factors associated with reduced odds of achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) at 6 months were identified (described as odds ratio and 95% confidence interval): demographic (female sex, 0·78, 0·66-0·93); social (unemployment, 0·67, 0·45-0·99); unemployment due to ill health (0·62, 0·48-0·82); ex- and current smoking (0·81, 0·66-0·99 and 0·79, 0·63-0·99, respectively); clinical factors (high weight, 0·99, 0·99-0·99); psoriasis of the palms ...Continue Reading
References
Jun 30, 1988·The New England Journal of Medicine·A LaupacisR S Roberts
Aug 29, 2002·Gastroenterology·Mansour A ParsiAaron Brzezinski
Jun 26, 2003·Alimentary Pharmacology & Therapeutics·I D R ArnottJ Satsangi
Jul 3, 2004·BMJ : British Medical Journal·Munir PirmohamedAlasdair M Breckenridge
Apr 19, 2005·Social Psychiatry and Psychiatric Epidemiology·Michael HöflerHans-Ulrich Wittchen
May 18, 2006·Rheumatology·K L HyrichUNKNOWN British Society for Rheumatology Biologics Register
Feb 12, 2009·PloS One·Emma C DaviesMunir Pirmohamed
Dec 22, 2010·Archives of Dermatology·Craig LeonardiJerry Bagel
Aug 9, 2011·Rheumatology International·Stefan KleinertBianca M Wittig
Feb 24, 2012·The British Journal of Dermatology·A D BurdenUNKNOWN BADBIR Study Group
May 16, 2012·Arthritis Research & Therapy·Sébastien OttavianiPhilippe Dieudé
Apr 30, 2013·The Journal of Dermatological Treatment·Vito Di LerniaElena Ficarelli
Jan 1, 2012·CPT: Pharmacometrics & Systems Pharmacology·Piet H van der Graaf
Aug 8, 2013·The Journal of Investigative Dermatology·Emily Edson-HerediaTomoko Maeda-Chubachi
Jul 22, 2014·The Journal of Dermatology·Yoshinori UmezawaHidemi Nakagawa
May 20, 2015·The British Journal of Dermatology·I Y K IskandarC E M Griffiths
Jun 9, 2015·The Journal of Investigative Dermatology·Richard B WarrenChristopher E M Griffiths
Sep 5, 2015·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Pauline A NelsonUNKNOWN IMPACT Team (Identification and Management of Psoriasis-Associated Co-morbidiTy)
Sep 15, 2015·The Journal of Dermatological Treatment·Ignacio García-DovalUNKNOWN BIOBADADERM Study Group
Jul 28, 2016·The British Journal of Dermatology·J ZweegersE M G J de Jong
Aug 16, 2016·BMC Musculoskeletal Disorders·Daniel F McWilliams, David A Walsh
Aug 24, 2016·Nature Communications·Solveig K SiebertsLara M Mangravite
Apr 4, 2017·The British Journal of Dermatology·I Y K IskandarC E M Griffiths
Apr 14, 2017·The British Journal of Dermatology·P A NelsonUNKNOWN Identification and Management of Psoriasis-Associated Co morbidiTy (IMPACT) team
May 2, 2017·The Journal of Investigative Dermatology·Zarif K Jabbar-LopezCatherine H Smith
Citations
May 8, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·A Di CesareF Prignano
Jan 30, 2020·Clinical and Translational Science·Shan PanUNKNOWN BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium
Jul 22, 2019·The British Journal of Dermatology·J M NorlinM Schmitt-Egenolf
Mar 4, 2020·The British Journal of Dermatology·Z Z N YiuUNKNOWN BADBIR Study Group
Aug 25, 2020·Archives of Toxicology·Jasna Grželj, Marija Sollner Dolenc
Jul 19, 2019·Frontiers in Immunology·Yisheng WongKenji Kabashima
Oct 20, 2019·The British Journal of Dermatology·R B WarrenC E M Griffiths
Apr 2, 2020·Expert Opinion on Drug Safety·Leila AsfourRichard B Warren
Jul 10, 2019·The British Journal of Dermatology·S K MahilUNKNOWN BADBIR study group and the PSORT consortium
Aug 9, 2020·The British Journal of Dermatology·V D ReddyJ Y Koo
Jun 7, 2020·Systematic Reviews·Ros WadeSofia Dias
Jul 10, 2019·The Journal of Dermatological Treatment·Andreas PinterMaximilian Reinhardt
Jun 12, 2020·The British Journal of Dermatology·E Veysey
Aug 20, 2020·The British Journal of Dermatology·R WadeS Dias
Oct 15, 2019·Arthritis Care & Research·Ana-Maria OrbaiLaure Gossec
Dec 15, 2020·The British Journal of Dermatology·Z Z N YiuUNKNOWN BADBIR Study Group
Oct 31, 2020·The Journal of International Medical Research·Hang ZhouYuwen Su
Mar 6, 2021·Dermatology and Therapy·Martina KojanovaUNKNOWN BIOREP Study Group
Mar 28, 2021·The Journal of Investigative Dermatology·Zenas Z N YiuUNKNOWN PSORT Consortium
Apr 5, 2021·Lancet·Christopher E M GriffithsJonathan N W N Barker
Apr 9, 2021·The British Journal of Dermatology·N GeifmanUNKNOWN BADBIR Study Group, on behalf of the PSORT Consortium
Jul 20, 2021·Expert Opinion on Biological Therapy·Arianna ZangrilliKetty Peris
May 16, 2021·The British Journal of Dermatology·G DalalUNKNOWN PSORT consortium
Jul 14, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·N WatsonS C Weatherhead
Aug 8, 2021·Nature Communications·Rosa Andres-EjarqueUNKNOWN PSORT Consortium
Jun 16, 2021·The British Journal of Dermatology·I Y K IskandarUNKNOWN on behalf the British Association of Dermatologists Biologics and Immunomodulators Register and Psoriasis Stratification to
Aug 22, 2021·Dermatologic Therapy·Nikolai LoftLone Skov
Oct 5, 2021·Dermatology and Therapy·Georgios KokolakisJose Manuel Carrascosa
Aug 20, 2021·The British Journal of Dermatology·S CroUNKNOWN APRICOT Study Group
Oct 14, 2021·Acta Dermato-venereologica·Christopher Willy SchwarzLone Skov
Nov 27, 2021·Dermatology and Therapy·Shinichi ImafukuHidemi Nakagawa